Participants 85 132 3
very platinum-sensitive ovarian cancer patients
Participants 234 342 5
patients with very platinum-sensitive recurrent ovarian cancer (ROC) enrolled in the phase III CALYPSO trial
Participants 369 382 5
international
Participants 414 525 5
women with ROC that relapsed >6 months following first- or second-line platinum- and paclitaxel-based therapies
Participants 886 959 3
259 very platinum-sensitive patients were included (n=131, CD; n=128, CP)
Participants 1819 1860 3
patients with very platinum-sensitive ROC
